AR027234A1 - Derivados de la toxina clostridial y metodos para el tratamiento del dolor - Google Patents

Derivados de la toxina clostridial y metodos para el tratamiento del dolor

Info

Publication number
AR027234A1
AR027234A1 ARP010100202A ARP010100202A AR027234A1 AR 027234 A1 AR027234 A1 AR 027234A1 AR P010100202 A ARP010100202 A AR P010100202A AR P010100202 A ARP010100202 A AR P010100202A AR 027234 A1 AR027234 A1 AR 027234A1
Authority
AR
Argentina
Prior art keywords
methods
pain
derivatives
treatment
clostridial toxin
Prior art date
Application number
ARP010100202A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR027234A1 publication Critical patent/AR027234A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los agentes para tratar el dolor, los métodos para producir los agentes y los métodos para tratar el dolor por la administracion a un paciente de unacantidad terapéuticamente efectiva del agente. El agente puede incluir una neurotoxina clostridial, o un componente o un fragmento o derivado de la misma,unido a un grupo activo, donde el grupo activo es seleccionado de un grupo que consiste de compuestos de transmision que pueden ser liberados de las neuronasen la transmision de las senales del dol or por las neuronas y los compuestos substancialmente similares a los compuestos de transmision.
ARP010100202A 2000-01-19 2001-01-17 Derivados de la toxina clostridial y metodos para el tratamiento del dolor AR027234A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/489,667 US7138127B1 (en) 2000-01-19 2000-01-19 Clostridial toxin derivatives and methods for treating pain

Publications (1)

Publication Number Publication Date
AR027234A1 true AR027234A1 (es) 2003-03-19

Family

ID=23944774

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100202A AR027234A1 (es) 2000-01-19 2001-01-17 Derivados de la toxina clostridial y metodos para el tratamiento del dolor

Country Status (4)

Country Link
US (13) US7138127B1 (es)
AR (1) AR027234A1 (es)
AU (1) AU2001227930A1 (es)
WO (1) WO2001053336A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
ES2277854T5 (es) 1999-08-25 2011-02-04 Allergan, Inc. Neurotoxinas recombinantes activables.
WO2001047512A2 (en) * 1999-12-08 2001-07-05 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
DE10019157A1 (de) * 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
AU2003259246A1 (en) * 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1740198A4 (en) * 2004-04-26 2009-03-04 Immuneregen Biosciences Inc ANTI-AGING EFFECT OF SUBSTANCE P
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7659092B2 (en) * 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
CA2601577A1 (en) 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
CA2658260A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP2009543556A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
CN101918021A (zh) * 2007-10-23 2010-12-15 阿勒根公司 使用经修饰的梭菌毒素治疗泌尿生殖系统神经疾病的方法
KR20100088683A (ko) * 2007-10-23 2010-08-10 알러간, 인코포레이티드 변형 클로스트리듐 독소를 사용한 만성 신경성 염증의 치료 방법
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
US9478108B2 (en) * 2008-11-10 2016-10-25 Archangel Device Llc Multi-directional, multi-functional, wearable safety lighting apparatus
PT3281953T (pt) 2009-03-13 2020-01-15 Allergan Inc Ensaios de base imunológica da actividade de endopeptidase redireccionada
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
EP2483666A1 (en) 2009-10-02 2012-08-08 Allergan, Inc. In vitro method of determining changes in a protein environment
HUE029962T2 (hu) 2010-01-25 2017-04-28 Allergan Inc Egyláncú fehérjék kétláncú formájúvá történõ intracelluláris konverziójának módszerei
NZ604322A (en) 2010-05-20 2015-01-30 Allergan Inc Degradable clostridial toxins
WO2012048246A1 (en) 2010-10-08 2012-04-12 Allergan, Inc. Reduction of antibody response against botulinum neurotoxin and variants thereof
EP3173095A1 (en) 2010-10-14 2017-05-31 Allergan, Inc. Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
EP2907504B1 (en) 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
WO2012135304A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Vagal nerve-based disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US20140170132A1 (en) 2012-12-18 2014-06-19 Allergan, Inc. Prophylatic treatment of herpes recurrence
US9447405B2 (en) 2013-03-08 2016-09-20 Wisconsin Alumni Research Foundation Regulation of specific spinal neurons regulating pain transmission via chimeric toxins
WO2015038916A2 (en) 2013-09-12 2015-03-19 Northeastern University Nanostructured bacteria-resistant polymer materials
CA2969463A1 (en) * 2014-12-09 2016-06-16 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
KR20190008225A (ko) * 2016-05-13 2019-01-23 델노바 인코퍼레이티드 화학적 신경차단으로 인한 부작용의 치료
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
AU2020340428A1 (en) * 2019-08-30 2022-03-03 AEON Biopharma, Inc. Neurotoxin compositions for use in treating headache

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466244A (en) * 1891-12-29 kelly
US4189426A (en) 1976-04-12 1980-02-19 Hoffmann-La Roche, Inc. Recombinant hormonal compositions and method
US4481139A (en) * 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
JPS60248659A (ja) 1984-05-25 1985-12-09 Microbial Chem Res Found ３−〔ｎ−（メルカプトアシル）〕アミノ−４−アリ−ル酪酸誘導体及びそれを有効成分とする鎮痛剤
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5410019A (en) * 1987-09-24 1995-04-25 The Administrators Of The Tulane-Educational Fund Therapeutic peptides
ES2087323T3 (es) 1991-02-19 1996-07-16 Takeda Chemical Industries Ltd Metodo para producir peptidos exentos de cisteina.
EP0823486A3 (en) 1991-06-27 2004-02-11 Genelabs Technologies, Inc. Method for inhibiting the binding of a dna-binding protein to duplex dna
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
US5891842A (en) 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3122319B2 (ja) 1994-05-02 2001-01-09 アソシエーティド ユニバーシティーズ，インコーポレイティド 錫−１１７ｍ−含有放射性治療剤
ATE292977T1 (de) 1994-05-09 2005-04-15 William J Binder Präsynaptische neurotoxine gegen migränekopfschmerzen
AU695623B2 (en) 1994-05-31 1998-08-20 Allergan, Inc. Modification of clostridial toxins for use as transport proteins
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5846216A (en) 1995-04-06 1998-12-08 G & P Technologies, Inc. Mucous membrane infusor and method of use for dispensing medications
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1998001754A1 (en) 1996-07-08 1998-01-15 University Of Massachusetts Dartmouth Novel proteins within the type e botulinum neurotoxin complex
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US5955368A (en) * 1998-04-06 1999-09-21 Wisconsin Alumni Research Foundation Expression system for clostridium species
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
ES2277854T5 (es) * 1999-08-25 2011-02-04 Allergan, Inc. Neurotoxinas recombinantes activables.
US7740868B2 (en) * 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20030180289A1 (en) * 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
TW540386U (en) * 2002-07-02 2003-07-01 Lu-Rung Liau Device for massaging human body
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
WO2006059093A2 (en) 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
CA2588292C (en) 2004-12-01 2019-01-15 Health Protection Agency Non-cytotoxic protein conjugates
CA2601577A1 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells

Also Published As

Publication number Publication date
AU2001227930A1 (en) 2001-07-31
WO2001053336A1 (en) 2001-07-26
US7833535B2 (en) 2010-11-16
US20060093625A1 (en) 2006-05-04
US7736659B2 (en) 2010-06-15
US20090010967A1 (en) 2009-01-08
US20060222666A1 (en) 2006-10-05
US7244436B2 (en) 2007-07-17
US20020068699A1 (en) 2002-06-06
US20080213311A1 (en) 2008-09-04
US7413742B2 (en) 2008-08-19
US7056729B2 (en) 2006-06-06
US7622127B2 (en) 2009-11-24
US7244437B2 (en) 2007-07-17
US7704512B2 (en) 2010-04-27
US20080317782A1 (en) 2008-12-25
US20070110769A1 (en) 2007-05-17
US20090042799A1 (en) 2009-02-12
US7425338B2 (en) 2008-09-16
US7138127B1 (en) 2006-11-21
US20060067929A1 (en) 2006-03-30
US7262291B2 (en) 2007-08-28
US20080095872A1 (en) 2008-04-24
US7780968B2 (en) 2010-08-24
US8017131B2 (en) 2011-09-13
US20080317783A1 (en) 2008-12-25
US20070259003A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
AR027234A1 (es) Derivados de la toxina clostridial y metodos para el tratamiento del dolor
Casley‐Smith et al. MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.
MXPA03002576A (es) Metodos para tratar lesiones musculares.
PT758900E (pt) Toxina botulinica para a reducao da dor de cabeca devida a enxaqueca
BR0110030A (pt) Método para tratamento de dor através da administração periférica de uma neurotoxina
ATE296093T1 (de) Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen
WO2002007759A3 (en) Clostridial toxin derivatives and methods for treating pain
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
HK1091418A1 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
AR028939A1 (es) Metodo para tratar un desorden pancreatico con una neurotoxina
BR0111698A (pt) Método para o tratamento de um distúrbio de movimento
EA200101089A1 (ru) Новый способ лечения
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
BR9510423A (pt) Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
MY119375A (en) Treatment of tinnitus using neuroprotective agents
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
BR9807796A (pt) Processos para tratar da incontinência urinária, de vertigem e da doença do movimento, e, composição farmacêutica.
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
BR9914794A (pt) Laxativo osmótico, não fermentado, para tratar e prevenir o câncer cólon-retal
SE0004101D0 (sv) New use
BR0209613A (pt) Composição para tratamento de dor em um mamìfero, e, método para redução ou eliminação de probabilidade de viciamento de um analgésico em um hospedeiro
BR0115215A (pt) Método para o tratamento de inflamações
WO2003103699A8 (en) USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária

Legal Events

Date Code Title Description
FB Suspension of granting procedure